Stock data
Dianthus Therapeutics, Inc. (DNTH)
Dianthus Therapeutics, Inc. (DNTH) reported revenue of US$2.04M and net income of -US$162.34M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$2.04M | — | -US$177.93M | -US$162.34M | — |
| 2024 | US$6.24M | — | -US$101.86M | -US$84.97M | — |
| 2023 | US$2.83M | — | -US$48.17M | -US$43.55M | — |
| 2022 | — | — | -US$29.70M | -US$28.48M | — |
| 2021 | — | — | -US$74.69M | -US$71.14M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$50.22M | — |
| 2026-03-31 | — | -US$40.83M | — |
| 2025-12-31 | US$0.28M | -US$64.43M | — |
| 2025-09-30 | US$0.40M | -US$36.77M | — |
| 2025-06-30 | US$0.19M | -US$31.63M | — |
| 2025-03-31 | US$1.16M | -US$29.51M | — |
| 2024-12-31 | US$1.33M | -US$28.44M | — |
| 2024-09-30 | US$2.17M | -US$25.17M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.